Newsletter: Weekly FDA Review (11/19/2009) - Subscribe/Unsubscribe
- Final Approvals (4)
- Rejections (2)
- Orphan Drug Designations (0)
- Recommended Approvals (1)
- Fast Track Status (0)
- Complete Response Letters (2)
- Tentative Approvals (1)
- Priority Reviews (1)
- New Drug Applications (1)
- Alerts, Recalls and Shortages (3)
Sentri7 monitors anticoagulation patients to help you comply with The Joint Commission's NPSG 3E. Get a demo.
1. Final Approvals
- Qutenza Approved for Post-Shingles Nerve Pain
HealthDay - Glenmark Generics gets FDA nod for Ciclopirox Olamine
Business Standard - Par Pharma gets FDA approval for generic Ultram ER
Associated Press - FDA Approves Lysteda To Treat Heavy Menstrual Bleeding
Medical News Today
- Genzyme's Pompe drug rejected
Reuters - CombinatoRx dives on FDA rejection
Bloomberg News
- FDA panel OKs new kids' pneumococcal shot
Associated Press
- Genentech, Biogen get FDA request on Rituxan
Associated Press - HGS's anthrax drug delayed by FDA
Washington Post
- Sun Pharma wins FDA tentative approval for generic leukemia drug
Trading Markets
- FDA to review Actelion's Zavesca for additional use
Reuters
- AstraZeneca asks for U.S. approval of Brilinta
Reuters
- ALERT: Clopidogrel
FDA Notice - ALERT: Genzyme
FDA Notice - Alert: Local Anesthetics
FDA Notice
E-mail This Newsletter to a Friend
PharmacyOneSource.com Privacy Policy
Pharmacy OneSource, 7780 Elmwood Ave. Ste #210 Middleton, WI 53562
Phone: (800) 654-8395
